According to the Complaint, Avedro, Inc. is a leading hybrid ophthalmic pharmaceutical and medical technology company focused on treating corneal disease and disorders and improving vision to reduce dependency on eyeglasses or contact lenses.

This action stems from a proposed transaction announced on August 7, 2019, pursuant to which Avedro will be acquired by Glaukos Corporation.

On August 7, 2019, Avedro’s Board of Directors caused the Company to enter into an agreement and plan of merger with Glaukos. Pursuant to the terms of the Merger Agreement, Avedro’s stockholders will receive 0.365 shares of Glaukos common stock for each share of Avedro common stock they own.

On September 17, 2019, Defendants filed a Form S-4 Registration Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Registration Statement omits material information with respect to the Proposed Transaction, which renders the Registration Statement false and misleading.

This case was voluntarily dismissed on January 13, 2020.